ALNY Quote, Financials, Valuation and Earnings

BridgeBio Pharma has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -143.55%. Alnylam Pharmaceuticals's return on equity of -- beat BridgeBio Pharma's return on equity of --.

Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 78.98%. Given that BridgeBio Pharma has higher upside potential than Alnylam Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Alnylam Pharmaceuticals's net income of -$57.5M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 48.69x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 24.92%. Alnylam Pharmaceuticals's return on equity of -- beat Biomarin Pharmaceutical's return on equity of 9.62%.

Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.91 which suggests that it could grow by 64%. Given that Biomarin Pharmaceutical has higher upside potential than Alnylam Pharmaceuticals, analysts believe Biomarin Pharmaceutical is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.1M. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Biomarin Pharmaceutical's net income of $185.7M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 21.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 3.92x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of 21.63%. Alnylam Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.72%.

Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 28.03%. Given that Pfizer has higher upside potential than Alnylam Pharmaceuticals, analysts believe Pfizer is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.38% to investors and pays a quarterly dividend of $0.43 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are smaller than Pfizer quarterly revenues of $13.7B. Alnylam Pharmaceuticals's net income of -$57.5M is lower than Pfizer's net income of $3B. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Vir Biotechnology has a net margin of -9.67% compared to Alnylam Pharmaceuticals's net margin of -6742.75%. Alnylam Pharmaceuticals's return on equity of -- beat Vir Biotechnology's return on equity of -45.02%.

Alnylam Pharmaceuticals has a consensus price target of $320.62, signalling upside risk potential of 9.58%. On the other hand Vir Biotechnology has an analysts' consensus of $17.88 which suggests that it could grow by 296.34%. Given that Vir Biotechnology has higher upside potential than Alnylam Pharmaceuticals, analysts believe Vir Biotechnology is more attractive than Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals has a beta of 0.169, which suggesting that the stock is 83.104% less volatile than S&P 500. In comparison Vir Biotechnology has a beta of 1.357, suggesting its more volatile than the S&P 500 by 35.699%.

Alnylam Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vir Biotechnology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alnylam Pharmaceuticals pays -- of its earnings as a dividend. Vir Biotechnology pays out -- of its earnings as a dividend.

Alnylam Pharmaceuticals quarterly revenues are $594.2M, which are larger than Vir Biotechnology quarterly revenues of $1.8M. Alnylam Pharmaceuticals's net income of -$57.5M is higher than Vir Biotechnology's net income of -$121M. Notably, Alnylam Pharmaceuticals's price-to-earnings ratio is -- while Vir Biotechnology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alnylam Pharmaceuticals is 16.02x versus 43.14x for Vir Biotechnology. Usually stocks with elevated PS ratios are considered overvalued.